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New reproductive technology has made the impossible possible. 
However, this comes with a cost, as many new reproductive advances 
have negative and positive implications. Advances have enabled 
people to improve on existing biological functions. With the advent 
of in vitro fertilisation in 1978, childless couples could be assisted 
with procreation.1 In the 1980s, scientists successfully removed early 
embryonic cells from human embryos for genetic screening against 
debilitating conditions. This can enable parents to prevent a child from 
inheriting serious genetic conditions. Used for other purposes, it can 
ensure that a child has specific characteristics such as a certain hair 
or eye colour, or it can even be used to create a new child who has the 
genetic capacity to assist a dying sibling – the so-called ‘saviour sibling’.2
New reproductive technology, such as pre-implantation genetic 
diagnosis (PGD), poses complex and competing religious, ethical, 
moral and scientific interests. Accordingly, there has been a move 
towards its legal regulation in various jurisdictions, including South 
Africa. We investigate the current and future South African legal 
frameworks to assess whether our law allows for pre-implantation 
diagnosis, effectively regulates the procedure, and protects the rights 
of both siblings, i.e. the saviour brother or sister (if born alive) and 
the dying or seriously ill child.
Pre-implantation diagnosis – new 
hope for parents with dying children
PGD was developed to screen embryos for severe irreversible genetic 
conditions (such as sickle-cell anaemia, Tay-Sachs disease, Duchenne’s 
muscular dystrophy and beta-thalassaemia) before in vitro fertilisation.3 
PGD can also screen for the existence of certain tissue types within the 
embryo, which enables a couple with a child needing a tissue transplant 
to ‘create’ a new baby who can serve as a compatible stem cell donor 
for its sick sibling. Parents are therefore able to use PGD together with 
in vitro fertilisation to screen their embryos and identify one or more 
that can provide an exact human leukocyte antigen (HLA) match for 
the ailing child.4 Stem cells from the new baby can be used as part of 
the treatment for the sick sibling.5 Removal of these cells at the birth of 
a child is painless and non-invasive.6
The main advantage of PGD is that it provides genetic information 
before implantation of an embryo into the womb and can ensure 
that only embryos that are an exact tissue match are transferred to 
a woman’s uterus. A couple can therefore avoid the difficult decision 
of either terminating the pregnancy should the fetus not be a match, 
or extending their family again, hoping that their next child has the 
desired tissue type.7
Current legal framework
South Africa has legislated on new reproductive issues through, 
among others, the Human Tissues Act8 (‘the Tissues Act’), the 
National Health Act9 (‘the Act’) and the Children’s Act.10
Currently, there is no reference in these laws to PGD. The Tissues 
Act in s18 - 23 allows the removal of blood and tissue for testing 
and states when and how such blood, tissues or gametes may be 
used. Although the Tissues Act does not refer specifically to PGD, 
one could argue that it is broad enough to accommodate the 
procedure. Furthermore, s19 enables the use of artificial fertilisation 
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Pre-implantation genetic diagnosis (PGD) is a technology used 
in conjunction with in vitro fertilisation to screen embryos for 
genetic conditions prior to transfer. It was initially developed 
to screen mutations for severe, irreversible, genetic conditions. 
Currently, PGD makes it possible to select against more than 100 
different genetic conditions. It has been proposed as a method 
for creating a tissue-matched child who can in turn serve as a 
compatible stem cell donor to save a sick sibling in need of a stem 
cell transplant. The advantage of this method is that it provides 
genetic information before implantation of an embryo into the 
womb, making it possible to ensure that only tissue-matched 
embryos are transferred to the uterus. A couple can therefore 
avoid the difficult choice of either terminating the pregnancy at 
a later point if the fetus is not a match, or extending their family 
again in the hope that their next child will be tissue compatible.
Many people have expressed disapproval of the use of PGD for 
this purpose, and it is associated with many conflicting interests 
including religion, ethics as well as legal regulation. In order 
to manage these issues some jurisdictions have created legal 
frameworks to regulate the use of this technology. Many of these 
are modelled on the UK’s Human Fertilisation and Embryology 
Authority and its guardian legislation.
This paper critiques the current and future South African legal 
framework to establish whether it is able to adequately regulate 
the use of PGD as well as guard against misuse of the technology. 
It concludes that changes are required to the future framework in 
order to ensure that it regulates the circumstances in which PGD 
may occur and that the Minister of Health should act expediently 
in finalising draft regulations which will regulate PGD in the 
future.
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as a reproductive procedure in which gametes are removed for 
transplantation into the body of another person.11
The Tissues Act also enables individuals to remove fetal or umbilical 
cord tissue for possible stem cell or other future therapy. It does not 
prohibit the third-party use of such material. It therefore does not 
prohibit the harvesting of stem cells from one child for use in another, 
as in a saviour sibling scenario. However, ministerial consent must be 
obtained for the removal of the tissue, and conditions may be imposed 
on such an authorisation.12 Accordingly, while fetal and umbilical cord 
tissue may be removed, the Minister may restrict its use.
The Act also does not refer to PGD but provides for the removal 
of gametes from a living person, which may only be used for ‘medical 
or dental purposes’.13 It prohibits the removal of such products from 
a person who is mentally ill, younger than 18 years old, and where 
the tissue is not replaceable by natural processes; or if the tissues are 
placental, embryonic/fetal tissue, stem cells or umbilical cord cells 
(excluding umbilical cord progenitor cells).14 Given that umbilical 
cord progenitor cells are excluded, such cells may be harvested at 
birth and stored for later use.
The Children’s Act describes rights for children as patients that 
protect children who participate in reproductive procedures, e.g. 
children who donate bone marrow to a sibling. This Act provides that 
children may consent independently to medical treatment from the 
age of 12 if they have ‘sufficient maturity’.15 Children may participate 
in decision making16 and are entitled to information on their health, 
which must be provided in an accessible manner.17 As a general 
principle, the Act provides that ‘[I]n all matters concerning the care, 
protection and well-being of a child the standard that the child’s best 
interest is of paramount importance, must be applied’.18
In summary: although the current legal framework is silent on the 
use of PGD, we argue that the procedure is not prohibited. However, 
PGD is effectively unregulated, as the Tissues Act only refers in 
broad terms to the testing of tissues and artificial insemination 
without linking them. The use of stem cell tissue is regulated, 
as parents require ministerial consent to harvest such material. 
Although this acts as a form of regulation, there is no guidance on 
the circumstances in which ministerial permission would be granted. 
Finally, the rights of child participants in the PGD are protected, as 
the Children’s Act requires them to be involved in health decisions 
and gives them the autonomy to decide on medical treatment (if 
over 12 years and sufficiently mature). However, the rights of saviour 
siblings, who may feel violated because they were ‘created’ to save an 
older sibling, are not protected, given the general legal principle that 
legal personality begins at birth.19
Future legal framework
The future legal framework will change if five draft regulations 
issued in terms of the Act20 are finalised and implemented, including 
draft regulations relating to the use of human biological material,21 
regulations relating to stem cell institutions or organisations,22 
regulations relating to tissue banks,23 regulations regarding the 
general control of human bodies, tissue, blood or blood products 
and gametes,24 and regulations relating to artificial fertilisation of 
persons.25 These were published for a 3-month public comment 
period on 1 April 2011. 
The draft Regulations relating to the use of human biological 
material are significant, as they refer expressly to PGD and will 
change the current framework in the following ways:
1.   Creating some clarity around PGD. The regulations provide that 
human biological material may be removed for the purposes of 
DNA, RNA and chromosome-based genetic testing.26 However, 
parents may not use genetic screening to select the sex of the 
embryo for implantation, unless this is to identify and avoid 
‘serious sex-linked or sex-limited genetic conditions’.27
2.   Ministerial consent is no longer required to remove and store 
umbilical cord progenitor cells. This enables the parents to harvest 
such cells at the birth of their child and determine how they will 
be used and, if needed, allows the cells to be donated to an ailing 
older sibling.28
3.   The regulations limit the persons and institutions that can perform 
the procedure by providing that the removal of a female gamete or 
ovum can only be done by a ‘competent person’,29 in this instance 
a ‘gynaecologist with training in reproductive endocrinology, and 
in the use of ovulation-inducing agents and the hormonal control 
of the menstrual cycle’.30 The procedure may only take place in an 
‘authorised’ or ‘prescribed institution’.31
Three draft regulations deal with the harvesting of stem cells 
or  tissues and their storage. The Regulations relating to stem cell 
institutions or organisations provide that no person shall use or 
acquire stem cells unless the institution is registered to perform 
this function with the Department of Health32 and keeps records of 
any stem cell donation.33 The Regulations relating to tissue banks 
provide that only registered institutions that have applied to the 
Director-General of Health to be tissue banks may screen or test 
tissues.34 Such institutions must store information on the results of 
tests (such as tissue typing tests) that are undertaken35 and keep 
a register of all tissue donors.36 The draft regulations provide an 
inspector of anatomy and investigating officers with powers to ensure 
that tissue banks maintain appropriate standards and comply with the 
regulations.37 In the future, therefore, tissue typing as part of the PGD 
process may only take place at an institution that is appropriately 
registered as a tissue bank. These draft regulations must be read with 
the Regulations regarding the general control of human bodies, 
tissue, blood or blood products and gametes, which provide that 
tissue, blood and gametes removed or withdrawn from living persons 
may only be used for medical and dental purposes.38 Removal must 
be with the written consent39 of the patient or a proxy.40
Finally, the draft Regulations relating to artificial fertilisation 
of persons create a new, highly regulated environment for artificial 
insemination. Regulation 3(1) provides that only a ‘competent person’ 
(i.e. a health professional who is registered with the Health Professions 
Council of South Africa and who is ‘(a) a medical practitioner 
specialising in gynaecology with accredited training in reproductive 
medicine; or (b) a medical scientist, medical technologist, [or] 
clinical technologist, with training in reproductive biology and 
related laboratory procedures’ may remove a gamete or cause a 
gamete to be removed from the body of a donor for the purpose 
of artificial fertilisation.41 The artificial insemination may only take 
place at an authorised institution42 and a record must be kept of the 
process.43 All births by artificial insemination must be recorded by 
the institution where the delivery took place.44 The mother of a child 
conceived by artificial insemination must ensure that the competent 
person who performed the procedure is informed of the birth and 
records the information.45
There is no change between the current and future frameworks 
regarding protection of the rights of the children involved in a saviour 
sibling process.
In summary: the new framework allows PGD, but not for sex-
selection purposes. Parents could use PGD to create a saviour sibling 
provided they use ‘competent persons’ at ‘authorised institutions’ 
and comply with the requirements regarding artificial insemination. 
Ministerial consent will no longer be required for the harvesting of 
stem cells.
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Discussion
The current legal framework appears to permit PGD as a procedure, 
but there are no regulations dealing with when it may be used. The 
new framework deals expressly with PGD by providing that it is 
permissible, except for sex selection. However, it is a concern that both 
provide insufficient guidance on the circumstances in which PGD is 
allowable. Although prohibiting sex selection is important, it deals with 
one narrow aspect of PGD and does not establish general principles on 
other circumstances in which PGD would be inappropriate.
The current framework focuses on the harvesting of stem cells, 
requiring ministerial consent but provides no guidance on the 
circumstances in which this consent ought to be provided. The 
Constitutional Court has found legislation that provides unfettered 
discretion to public officials to be inconsistent with the Constitution. 
In Dawood v Minister of Home Affairs,46 the court held that:
In the future, the draft regulations impose extensive regulation on 
the removal, use and donation of blood, tissues and gametes. Most 
of this regulation is thorough: (i) only allowing certain registered 
persons and institutions to perform procedures such as PGD, 
tissue typing and artificial insemination; and (ii) requiring the 
documentation of donations and procedures, e.g. at tissue banks. 
The Department of Health will therefore control work in this field 
through its registration procedures and the monitoring of databases. 
While this type of regulation has some value, it fails to set normative 
standards for the circumstances in which the procedures may be 
undertaken. Earlier draft regulations47 addressed this as the Minister 
could only approve the harvesting of fetal and umbilical cord tissue 
on the recommendation of a sub-committee within the National 
Health Research Ethics Committee. This brought our framework 
approach closer to other jurisdictions in which powers to grant or 
refuse permission for certain reproductive procedures are devolved 
to a specialist council. Sadly, this important innovation was excluded 
from the current draft regulations, leaving no principles to guide the 
decision-making relating to PGD.
South Africa can learn from other countries in this regard, e.g. the 
Human Fertilisation and Embryology Authority (HFEA) in the UK 
established a committee to license treatments or research projects.48 
The HFEA provides that PGD with HLA typing may be permitted if:
1.   The affected child is suffering from a severe or life-threatening 
disease of a sufficient seriousness to justify the use of PGD.
2.   The embryos conceived in the course of treatment should 
themselves be at risk from the condition by which the existing 
child is affected.
3.   All other possibilities of treatment and sources of tissue for the 
affected child have been explored. 
4.   The techniques should not be available where the intended 
recipient is a parent.
5.   Only cord blood should be harvested for purposes of the 
treatment, and not other tissues or organs.
6.   Appropriate counselling around the implications of PGD should 
be a requirement for couples undergoing this treatment.
7.  Families should be encouraged to participate in follow-up studies.
8.   Embryos should not be genetically modified to provide a tissue 
match.49
Conclusions and recommendations
PGD is an important medical innovation enabling families to 
eradicate serious genetic diseases from their family trees and, in 
extreme situations, to create a child that can act as a tissue donor for 
a sick sibling. However, it raises complex social and ethical issues 
that require careful consideration to ensure the affected children are 
protected. 
Sadly, the South African legal framework is betwixt and between 
the new and the old. The old, in the form of the Tissues Act, caters 
inadequately for PGD; and new regulations under the Act have 
not been finalised and are in some respects inadequate. This leaves 
the law lagging behind new reproductive technology. Although 
this results in legal uncertainty, it offers an opportunity to change 
the framework before the draft regulations are finalised through 
submitting public comments. We propose the following changes to 
the draft April 2011 regulations:
1.   Clearly establish PGD tissue typing as an acceptable therapy for 
use in children, rather than focusing narrowly on sex selection.
2.   Establish principles to guide when PGD and the use of stem cells 
will be acceptable, or
3.   Require the establishment of a sub-committee within the National 
Health Research Ethics Council to issue such guidance, as done by 
the HFEA in the UK.
PGD offers an unparalleled opportunity for families to save their 
sick children. However, it comes with the possible social cost of 
children who may feel that they have been ‘created’ not because they 
have inherent dignity and value but because their tissues are needed. 
Allowing the law to lag behind medical advances fails families with 
ill children and saviour siblings. Regulation of PGD is required to 
balance these conflicting interests. The Minister of Health should act 
urgently in revising and finalising the draft regulations to prevent 
the procedure from being used inappropriately and provoking a 
subsequent public outcry.
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